Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats Buys 10,000 Shares

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) CEO Lonnel Coats bought 10,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were purchased at an average price of $9.91 per share, with a total value of $99,100.00. Following the purchase, the chief executive officer now owns 42,985 shares of the company’s stock, valued at approximately $425,981.35. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Lonnel Coats also recently made the following trade(s):

  • On Friday, September 15th, Lonnel Coats bought 30,000 shares of Lexicon Pharmaceuticals stock. The shares were purchased at an average price of $12.54 per share, with a total value of $376,200.00.

Lexicon Pharmaceuticals, Inc. (LXRX) opened at $10.45 on Monday. The company has a quick ratio of 1.65, a current ratio of 1.66 and a debt-to-equity ratio of 1.09. Lexicon Pharmaceuticals, Inc. has a 12 month low of $8.07 and a 12 month high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative net margin of 165.69% and a negative return on equity of 111.68%. The company had revenue of $26.94 million during the quarter, compared to the consensus estimate of $27.97 million. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. Lexicon Pharmaceuticals’s revenue for the quarter was down 2.8% on a year-over-year basis. research analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in LXRX. Cubist Systematic Strategies LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the third quarter valued at about $149,000. Parametric Portfolio Associates LLC purchased a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at about $182,000. C WorldWide Group Holding A S raised its holdings in shares of Lexicon Pharmaceuticals by 49.6% in the third quarter. C WorldWide Group Holding A S now owns 16,146 shares of the biopharmaceutical company’s stock valued at $198,000 after buying an additional 5,353 shares during the last quarter. First Mercantile Trust Co. raised its holdings in shares of Lexicon Pharmaceuticals by 11.2% in the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the last quarter. Finally, Cim Investment Mangement Inc. purchased a new stake in shares of Lexicon Pharmaceuticals in the second quarter valued at about $262,000.

A number of equities analysts recently commented on LXRX shares. Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Wedbush reiterated an “outperform” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, October 5th. BidaskClub downgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 10th. Finally, Needham & Company LLC restated a “buy” rating and issued a $21.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Sunday, September 17th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $28.50.

TRADEMARK VIOLATION NOTICE: “Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats Buys 10,000 Shares” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://weekherald.com/2017/12/04/lonnel-coats-purchases-10000-shares-of-lexicon-pharmaceuticals-inc-lxrx-stock.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply